{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:08:56Z","timestamp":1791155336225,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1007\/s11095-004-1877-8","type":"journal-article","created":{"date-parts":[[2005,3,31]],"date-time":"2005-03-31T07:41:06Z","timestamp":1112254866000},"page":"397-404","source":"Crossref","is-referenced-by-count":10,"title":["Significant Intestinal Excretion, One Source of Variability in Pharmacokinetics of COL-3, a Chemically Modified Tetracycline"],"prefix":"10.1007","volume":"22","author":[{"given":"Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,3,21]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/00220345870660080401","volume":"66","author":"L. M. Golub","year":"1987","unstructured":"1. L. M. Golub, T. F. McNamara, G. D?Angelo, R. A. Greenwald, and N. S. Ramamurthy. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J. Dent. Res. 66:1310?1314 (1987).","journal-title":"J. Dent. Res."},{"key":"CR2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ijc.10168","volume":"98","author":"B. L. Lokeshwar","year":"2002","unstructured":"2. B. L. Lokeshwar, M. G. Selzer, B. Q. Zhu, N. L. Block, and L. M. Golub. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int. J. Cancer 98:297?309 (2002).","journal-title":"Int. J. Cancer"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1749-6632.1999.tb07759.x","volume":"878","author":"P. Maisi","year":"1999","unstructured":"3. P. Maisi, M. Kiili, S. M. Raulo, E. Pirila, and T. Sorsa. MMP inhibition by chemically modified tetracycline-3 (CMT-3) in equine pulmonary epithelial lining fluid. Ann. N. Y. Acad. Sci. 878:675?677 (1999).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"CR4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/0929867013373660","volume":"8","author":"H. M. Lee","year":"2001","unstructured":"4. H. M. Lee, L. M. Golub, J. Cao, O. Teronen, M. Laitinen, T. Salo, S. Zucker, and T. Sorsa. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer. Curr. Med. Chem. 8:257?260 (2001).","journal-title":"Curr. Med. Chem."},{"key":"CR5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/A:1006588708131","volume":"16","author":"R. E. Seftor","year":"1998","unstructured":"5. R. E. Seftor, E. A. Seftor, J. E. De Larco, D. E. Kleiner, J. Leferson, W. G. Stetler-Stevenson, T. F. McNamara, L. M. Golub, and M. J. Hendrix. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin. Exp. Metastasis 16:217?225 (1998).","journal-title":"Clin. Exp. Metastasis"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2001.19.2.584","volume":"19","author":"M. A. Rudek","year":"2001","unstructured":"6. M. A. Rudek, W. D. Figg, V. Dyer, W. Dahut, M. L. Turner, S. M. Steinberg, D. J. Liewehr, D. R. Kohler, J. M. Pluda, and E. Reed. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J. Clin. Oncol. 19:584?592 (2001).","journal-title":"J. Clin. Oncol."},{"key":"CR7","first-page":"153","volume":"20","author":"M. Cianfrocca","year":"2002","unstructured":"7. M. Cianfrocca, T. P. Cooley, J. Y. Lee, M. A. Rudek, D. T. Scadden, L. Ratner, J. M. Pluda, W. D. Figg, S. E. Krown, and B. J. Dezube. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi?s sarcoma: a phase I AIDS malignancy consortium study. J. Clin. Oncol. 20:153?159 (2002).","journal-title":"J. Clin. Oncol."},{"key":"CR8","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1158\/1078-0432.CCR-04-0804","volume":"10","author":"S. Syed","year":"2004","unstructured":"8. S. Syed, C. Takimoto, M. Hidalgo, J. Rizzo, J. G. Kuhn, L. A. Hammond, G. Schwartz, A. Tolcher, A. Patnaik, S. G. Eckhardt, and E. K. Rowinsky. A phase I and pharmacokinetic study of col-3 (metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin. Cancer Res. 10:6512?6521 (2004).","journal-title":"Clin. Cancer Res."},{"key":"CR9","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1023\/A:1020901328583","volume":"19","author":"J. Li","year":"2002","unstructured":"9. J. Li, H. Huynh, and E. Chan. Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration. Pharm. Res. 19:1655?1662 (2002).","journal-title":"Pharm. Res."},{"key":"CR10","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/0091270003256675","volume":"43","author":"M. A. Rudek","year":"2003","unstructured":"10. M. A. Rudek, J. Venitz, Y. Ando, E. Reed, J. M. Pluda, and W. D. Figg. Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. J. Clin. Pharmacol. 43:1124?1135 (2003).","journal-title":"J. Clin. Pharmacol."},{"key":"CR11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jchromb.2003.10.066","volume":"799","author":"J. Li","year":"2004","unstructured":"11. J. Li, H. Huynh, and E. Chan. Reversed-phase liquid chromatography method to determine COL-3, a matrix metalloproteinase inhibitor, in biological samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 799:311?321 (2004).","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"CR12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-4899-3188-7_8","volume-title":"Introduction to Drug Metabolims","author":"G. G. Gibson","year":"1986","unstructured":"12. G. G. Gibson and P. Skett. Techniques and experiments illustrating drug metabolism. In P. Skett (ed.), Introduction to Drug Metabolims, Chapman and Hall, New York, 1986, pp. 239?284."},{"key":"CR13","first-page":"119","volume-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"M. Rowland","year":"1995","unstructured":"13. M. Rowland and T. Tozer. Absorption. In M. Rowland and T. Tozer (eds.), Clinical Pharmacokinetics: Concepts and Applications, Williams & Wilkins, London, 1995, pp. 119?136."},{"key":"CR14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1056-8719(99)00005-2","volume":"40","author":"Q. Zhou","year":"1998","unstructured":"14. Q. Zhou and E. Chan. Accuracy of repeated blood sampling in rats: a new technique applied in pharmacokinetic\/pharmacodynamic studies of the interaction between warfarin and co-enzyme Q10. J. Pharmacol. Toxicol. Methods 40:191?199 (1998).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1022254617664","volume":"20","author":"J. Xu","year":"2003","unstructured":"15. J. Xu, M. L. Go, and L. Y. Lim. Modulation of digoxin transport across Caco-2 cell monolayers by citrus fruit juices: lime, lemon, grapefruit, and pummelo. Pharm. Res. 20:169?176 (2003).","journal-title":"Pharm. Res."},{"key":"CR16","volume-title":"Evaluation of the pharmacokinetic-pharmacodynamic relationship for the matrix metalloproteinase inhibitory effect of COL-3 following oral administration to patients with refractory metastatic cancer.","author":"M. A. Rudek","year":"2001","unstructured":"16. M. A. Rudek. Evaluation of the pharmacokinetic-pharmacodynamic relationship for the matrix metalloproteinase inhibitory effect of COL-3 following oral administration to patients with refractory metastatic cancer. Department of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, 2001."},{"key":"CR17","first-page":"16","volume-title":"The Excretory Function of Bile","author":"R. Smith","year":"1973","unstructured":"17. R. Smith. Factors affecting biliary excretion. In R. Smith (ed.), The Excretory Function of Bile, Chapman and Hall, London, 1973, pp. 16?34."},{"key":"CR18","first-page":"142","volume":"10","author":"H. J. Nelis","year":"1982","unstructured":"18. H. J. Nelis and A. P. De Leenheer. Metabolism of minocycline in humans. Drug Metab. Dispos. 10:142?146 (1982).","journal-title":"Drug Metab. Dispos."},{"key":"CR19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0378-4347(00)84428-X","volume":"274","author":"R. Bocker","year":"1983","unstructured":"19. R. Bocker. Analysis and quantitation of a metabolite of doxycycline in mice, rats, and humans by high-performance liquid chromatography. J. Chromatogr. 274:255?262 (1983).","journal-title":"J. Chromatogr."},{"key":"CR20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/0929867013373615","volume":"8","author":"J. Chen","year":"2001","unstructured":"20. J. Chen, M. Bookbinder, M. E. Ryan, L. M. Golub, R. Ashley, and N. S. Ramamurthy. Biodistribution of radiolabeled [(3)H] CMT-3 in rats. Curr. Med. Chem. 8:253?256 (2001).","journal-title":"Curr. Med. Chem."},{"key":"CR21","first-page":"584","volume":"296","author":"R. H. Stephens","year":"2001","unstructured":"21. R. H. Stephens, C. A. O?Neill, A. Warhurst, G. L. Carlson, M. Rowland, and G. Warhurst. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther. 296:584?591 (2001).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"CR22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1476-5381.1996.tb15775.x","volume":"119","author":"U. Mayer","year":"1996","unstructured":"22. U. Mayer, E. Wagenaar, J. H. Beijnen, J. W. Smit, D. K. Meijer, J. van Asperen, P. Borst, and A. H. Schinkel. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br. J. Pharmacol. 119:1038?1044 (1996).","journal-title":"Br. J. Pharmacol."},{"key":"CR23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1023\/A:1023847521767","volume":"20","author":"K. Arimori","year":"2003","unstructured":"23. K. Arimori, N. Kuroki, M. Hidaka, T. Iwakiri, K. Yamsaki, M. Okumura, H. Ono, N. Takamura, M. Kikuchi, and M. Nakano. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm. Res. 20:910?917 (2003).","journal-title":"Pharm. Res."},{"key":"CR24","first-page":"2598","volume":"6","author":"L. Zuylen van","year":"2000","unstructured":"24. L. van Zuylen, J. Verweij, K. Nooter, E. Brouwer, G. Stoter, and A. Sparreboom. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin. Cancer Res. 6:2598?2603 (2000).","journal-title":"Clin. Cancer Res."},{"key":"CR25","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.94.5.2031","volume":"94","author":"A. Sparreboom","year":"1997","unstructured":"25. A. Sparreboom, J. van Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, and O. van Tellingen. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94:2031?2035 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","volume":"175","author":"P. Artursson","year":"1991","unstructured":"26. P. Artursson and J. Karlsson. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175:880?885 (1991).","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-004-1877-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-004-1877-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-004-1877-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T01:38:43Z","timestamp":1559353123000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-004-1877-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["1877"],"URL":"https:\/\/doi.org\/10.1007\/s11095-004-1877-8","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}